These changes inhibited intestinal FXR signaling and improved metabolic dysfunction, hinting the alterations in microbiome composition and the subsequent impact on secondary BAs production may be an important factor in the prevention of CRC by metformin (150). Here, NR1H4 is linked to colorectal carcinoma.